The State
Institute for Drug Control (the Institute) discontinued reimbursement for
specific variants of a medicinal product from the allergen group following an
application by the manufacturer. As part of the
proceedings, the Institute assessed market availability and the public
interest. The analysis confirmed that discontinuing reimbursement would not
put patients at risk, as fully...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
